Loading...
•
Dec 31, 2022
Zevra Q4 2022 Earnings Report
Zevra Therapeutics reported its financial results, highlighting revenue growth and strategic advancements.
Key Takeaways
Zevra Therapeutics reported a net revenue of $2.3 million for Q4 2022, primarily driven by reimbursements from the French early access program for arimoclomol, AZSTARYS® royalty revenues, and consulting fees. The company's cash, cash equivalents, and investments totaled $102.9 million as of December 31, 2022, extending the cash runway into 2026.
Net revenue for Q4 2022 was $2.3 million.
R&D expenses were $6.4 million for Q4 2022.
G&A expenses were $5.1 million for Q4 2022.
Cash, cash equivalents, and investments totaled $102.9 million as of December 31, 2022, extending the cash runway into 2026.
Zevra
Zevra
Forward Guidance
Zevra Therapeutics anticipates potential milestones in 2023, including the arimoclomol NDA resubmission as early as Q3 2023 and preliminary data from the KP1077 Phase 2 Trial as early as Q3 2023.
Positive Outlook
- Arimoclomol NDA resubmission on track to be filed as early as Q3 2023
- KP1077 Phase 2 Trial on track to deliver preliminary data as early as Q3 2023 and top-line data as early as year-end 2023
- AZSTARYS® royalty revenue growing with one or more revenue milestones expected to be achieved in 2023
- Cash runway extends into 2026
- Potential to realize milestone and royalty revenue from AZSTARYS®